FirstSight
Commercial- Indications
- Colorectal cancer
Company intelligence / Profile preview
CellMax Life’s FirstSight™ blood test demonstrated strong early results for detecting both colorectal cancers and precancerous polyps in a prospective multisite trial of 350 individuals. The company is now planning larger pivotal studies to further validate performance prior to commercialization in the United States. Their technology has shown promise for non-invasive early detection, which could significantly improve compliance with screening guidelines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CellMax Life.